KRAS and colorectal carcinoma: These findings imply that KRAS MT CRC cells may evade the protective effects of E2 through GPER1 under nutrient-poor conditions, positioning GPER1 and ASNS as potential therapeutic targets for KRAS MT CRC (Fig. 4).